What is MRSA?
MRSA (methicillin-resistant Staphylococcus aureus) is a strain of staph bacteria that has evolved resistance to the standard beta-lactam antibiotics — methicillin, oxacillin, penicillin and amoxicillin — used to treat ordinary staph infections.
The name is a mouthful, but the meaning is simple. Staphylococcus aureus — "staph" for short — is a common bacterium that lives on the skin and in the nose of roughly one in three healthy people. Most of the time it causes no problem. When it does cause infection, it is usually a boil, a wound infection, or an abscess that clears with a routine antibiotic. MRSA is the version that no longer clears with those routine antibiotics.
MRSA is a bacterium, not a virus. Antivirals such as those used for flu or COVID-19 have no effect on it. Its resistance comes from a gene called mecA, which produces an altered target protein that penicillin-family drugs cannot bind to. Decades of antibiotic use in hospitals, in the community and in livestock farming have selected for these resistant strains.
Doctors usually split MRSA into two overlapping types. Healthcare-associated MRSA (HA-MRSA) spreads in hospitals, nursing homes and dialysis units, typically via catheters, surgical wounds and shared equipment. Community-associated MRSA (CA-MRSA) spreads outside healthcare — in gyms, prisons, households and sports teams — and more often shows up as painful skin abscesses in otherwise healthy people. Read more on what MRSA looks like, how it spreads and how it is treated.
MRSA at a glance
- Full name
- Methicillin-resistant Staphylococcus aureus
- Type
- Bacterium (Gram-positive coccus) — not a virus
- First identified
- 1961, shortly after methicillin entered clinical use
- Main reservoirs
- Human skin and nose; hospitals; livestock (LA-MRSA)
- Main routes
- Skin-to-skin contact, contaminated surfaces, shared items, indwelling devices
- Resistant to
- Methicillin, oxacillin, penicillin, amoxicillin and most beta-lactams
- Still treatable with
- Vancomycin, daptomycin, linezolid, clindamycin, doxycycline, TMP-SMX
- Mortality (invasive)
- Roughly 15–20% even with modern treatment
MRSA, in plain answers
Short, evidence-based answers to the questions people ask most about MRSA. Each links to a deeper guide.
What does MRSA stand for?
→MRSA stands for methicillin-resistant Staphylococcus aureus — a strain of the common staph bacterium that has become resistant to methicillin and related beta-lactam antibiotics (penicillin, oxacillin, amoxicillin).
Is MRSA a virus or a bacterium?
→MRSA is a bacterium, not a virus. It is a resistant strain of Staphylococcus aureus, which lives harmlessly on the skin and in the nose of roughly one in three people. Antivirals do not work on it — only certain antibiotics do.
What causes MRSA?
→MRSA is caused by Staphylococcus aureus bacteria that carry the mecA gene, producing an altered penicillin-binding protein that beta-lactam antibiotics cannot bind to. Decades of antibiotic use in healthcare, the community and agriculture selected for these resistant strains.
How is MRSA different from a normal staph infection?
→Symptoms are similar — boils, abscesses, wound infections — but MRSA does not respond to the front-line antibiotics used for ordinary staph. Doctors have to use alternatives such as vancomycin, clindamycin, doxycycline or linezolid.
How do you catch MRSA?
→MRSA spreads mainly by direct skin-to-skin contact and by touching contaminated surfaces or shared items — towels, razors, gym equipment, hospital bed rails. It can also be carried silently in the nose and passed on without symptoms.
How is MRSA treated?
→Small skin abscesses are usually drained and may need no antibiotics. More serious infections need MRSA-active antibiotics — commonly vancomycin or daptomycin for invasive disease, or oral options like clindamycin, doxycycline, TMP-SMX or linezolid for skin infections.
Latest on MRSA
- 01Jul 21, 2026
- 02Jul 14, 2026
- 03Jul 13, 2026Design, synthesis, and biological evaluation of pentacyclic triterpenoids-triphenylphosphine derivatives as antibacterial agents to combat MRSANaunyn-Schmiedeberg's archives of pharmacology
- 04Jul 13, 2026Comparative study of recurrent mastitis caused by MRSA and non-MRSA Staphylococcus aureus in Holstein-Fresian cowsThe Journal of veterinary medical science
- 05Jul 13, 2026
- 06Jul 13, 2026
- 07Jul 12, 2026
- 08Jul 12, 2026
- 09Jul 11, 2026
- 10Jul 11, 2026LAMP-Based Two-DNA-Fragment Fusion and Its Application in Nucleic Acid DetectionACS synthetic biology
- 11Jul 11, 2026
- 12Jul 10, 2026
The weekly MRSA briefing
One email every Thursday: the most important new research, outbreak updates, and guideline changes — distilled.
